Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARDNASDAQ:ANNXNASDAQ:NVCTNASDAQ:OTLK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$10.50+4.9%$9.11$4.88▼$19.58$227.81MN/A112,131 shs22,053 shsANNXAnnexon$2.11+2.4%$1.86$1.29▼$7.85$231.50M1.241.79 million shs951,998 shsNVCTNuvectis Pharma$9.83-1.2%$9.36$4.44▼$11.80$205.39M-0.11127,541 shs83,412 shsOTLKOutlook Therapeutics$1.60-2.4%$1.46$0.87▼$9.25$53.71M0.39763,103 shs1.86 million shs20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+4.90%+6.17%+23.24%-25.11%+1,049,999,900.00%ANNXAnnexon+2.43%+4.98%+14.67%-24.91%-56.76%NVCTNuvectis Pharma-1.21%-0.41%-5.57%+29.51%+47.38%OTLKOutlook Therapeutics-2.44%-8.57%+3.23%+2.56%-80.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AANNXAnnexon1.8705 of 5 stars3.51.00.00.03.10.80.6NVCTNuvectis Pharma2.201 of 5 stars3.50.00.00.01.15.00.6OTLKOutlook Therapeutics1.7608 of 5 stars3.43.00.00.01.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 3.00Buy$31.25197.62% UpsideANNXAnnexon 3.00Buy$12.50492.42% UpsideNVCTNuvectis Pharma 3.00Buy$17.0072.94% UpsideOTLKOutlook Therapeutics 2.80Moderate Buy$10.20537.50% UpsideCurrent Analyst Ratings BreakdownLatest OTLK, ANNX, NVCT, and AARD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/15/2025AARDAardvark TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.005/14/2025ANNXAnnexonHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $14.005/13/2025ANNXAnnexonNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $11.004/30/2025NVCTNuvectis PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $15.004/2/2025NVCTNuvectis PharmaMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.004/1/2025AARDAardvark TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.004/1/2025AARDAardvark TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.003/27/2025AARDAardvark TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.003/17/2025NVCTNuvectis PharmaLaidlawSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.003/10/2025AARDAardvark TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$29.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AANNXAnnexonN/AN/AN/AN/A$3.20 per shareN/ANVCTNuvectis PharmaN/AN/AN/AN/A$0.70 per shareN/AOTLKOutlook TherapeuticsN/AN/AN/AN/A($1.57) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AANNXAnnexon-$134.24M-$1.18N/AN/AN/AN/A-38.99%-33.90%8/11/2025 (Estimated)NVCTNuvectis Pharma-$22.26M-$1.13N/AN/AN/AN/A-155.80%-104.02%8/5/2025 (Estimated)OTLKOutlook Therapeutics-$75.37M-$0.91N/AN/AN/AN/AN/A-225.12%N/ALatest OTLK, ANNX, NVCT, and AARD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q2 2025OTLKOutlook Therapeutics-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A5/14/2025N/AAARDAardvark Therapeutics-$0.70-$0.71-$0.01-$0.71N/AN/A5/12/2025Q1 2025ANNXAnnexon-$0.30-$0.37-$0.07-$0.37N/AN/A5/6/2025Q1 2025NVCTNuvectis Pharma-$0.30-$0.27+$0.03-$0.27N/AN/A3/4/2025Q4 2024NVCTNuvectis Pharma-$0.28-$0.36-$0.08-$0.36N/AN/A3/3/2025Q4 2024ANNXAnnexon-$0.28-$0.33-$0.05-$0.33N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AANNXAnnexonN/AN/AN/AN/AN/ANVCTNuvectis PharmaN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/AN/AN/AANNXAnnexonN/A17.1717.18NVCTNuvectis PharmaN/A2.742.74OTLKOutlook TherapeuticsN/A0.320.64Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AANNXAnnexonN/ANVCTNuvectis Pharma96.77%OTLKOutlook Therapeutics11.20%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AANNXAnnexon11.87%NVCTNuvectis Pharma35.78%OTLKOutlook Therapeutics4.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.70 millionN/AN/AANNXAnnexon60109.71 million93.09 millionOptionableNVCTNuvectis Pharma820.89 million12.41 millionNot OptionableOTLKOutlook Therapeutics2033.57 million30.48 millionOptionableOTLK, ANNX, NVCT, and AARD HeadlinesRecent News About These CompaniesOutlook Therapeutics announces public stock offeringMay 24 at 3:25 AM | investing.comOutlook Therapeutics, Inc. Announces Underwritten Public Offering of Common Stock and WarrantsMay 24 at 3:25 AM | nasdaq.comOutlook Therapeutics announces proposed public offering of common stock, warrantsMay 23 at 12:21 PM | msn.comOutlook Therapeutics drops 17%, prices $13M stock offeringMay 23 at 12:21 PM | msn.comOutlook Therapeutics® Announces Pricing of $13.0 Million Public OfferingMay 23 at 6:30 AM | globenewswire.comOutlook Therapeutics® Announces Proposed Public Offering of Common Stock and WarrantsMay 22 at 4:01 PM | globenewswire.comTang Capital Management LLC Has $345,000 Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK)May 21 at 6:07 AM | marketbeat.comOutlook Therapeutics, Inc.: Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deOutlook Therapeutics (OTLK) Projected to Post Quarterly Earnings on WednesdayMay 16, 2025 | marketbeat.comOutlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate UpdateMay 15, 2025 | globenewswire.comWhy Outlook Therapeutics, Inc.’s (OTLK) Stock Is Down 6.40%May 15, 2025 | aaii.comMicrosoft shares big update on new Outlook enable/disable optionMay 12, 2025 | windowsreport.comWindows New Outlook will soon get offline Calendar supportMay 9, 2025 | windowsreport.comWant to use both new and classic Outlook apps? Soon, says MicrosoftMay 7, 2025 | msn.comClassic Outlook Gets a Smoother Experience in Windows 11May 7, 2025 | channelnews.com.auClassic Outlook will soon be easier to use in Windows 11May 7, 2025 | digitaltrends.comFDA accepts biologics license application from Outlook Therapeutics for ONS-5010 for the treatment of wet AMDApril 10, 2025 | ophthalmologytimes.comOutlook Therapeutics announces acceptance of BLA by U.S. FDA for ONS-5010April 8, 2025 | markets.businessinsider.comOutlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMDApril 8, 2025 | globenewswire.comOutlook Therapeutics management to meet virtually with BTIGMarch 21, 2025 | markets.businessinsider.comOutlook Therapeutics files to sell 21.72M shares of common stock for holdersMarch 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeOTLK, ANNX, NVCT, and AARD Company DescriptionsAardvark Therapeutics NASDAQ:AARD$10.50 +0.49 (+4.90%) As of 05/23/2025 04:00 PM EasternAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Annexon NASDAQ:ANNX$2.11 +0.05 (+2.43%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.08 -0.03 (-1.42%) As of 05/23/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Nuvectis Pharma NASDAQ:NVCT$9.83 -0.12 (-1.21%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.85 +0.02 (+0.15%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.Outlook Therapeutics NASDAQ:OTLK$1.60 -0.04 (-2.44%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.59 -0.01 (-0.63%) As of 05/23/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain Advance Auto Parts Jumps on Surprise Earnings Beat Costco Stock at $1K: Dominance or Danger Zone? Williams-Sonoma: A Fundamentally Good Buy On Sale Now Snowflake Breaks Out! Can It Drift Higher in 2025 and Beyond? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
